We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Changes of CD4+T Lymphocyte Subsets in Septic Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2011 by Chinese PLA General Hospital.
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: December 19, 2011
Last Update Posted: December 19, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Chinese PLA General Hospital
The purpose of this study is to explore the value of CD4+T lymphocyte subsets in cell immunity in the patients with sepsis.There are immunoparalysis in septic patients,the important player is the change of CD4+T lymphocyte,this immunoparalysis state contribute to the illness progress and outcome. Comprehend the change regularity of septic patients' cell immunity can guide fiter and correcter treatment.

Sepsis SIRS(Systemic Inflammatory Response Syndrome)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Role of CD4+T Lymphocyte Subsets in Cell Immunity in Patients With Sepsis

Resource links provided by NLM:

Further study details as provided by Chinese PLA General Hospital:

Study Start Date: August 2011
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
SIRS + infection
not SIRS and have no infection


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All subjects were selected from among inpatients who were hospitalized between March 2010 and March 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's Liberation Army (CPLA) General Hospital.

Inclusion Criteria:

  • Male and female aged 18 years old and over;
  • Fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °C or lower than 36 °C (b)respiratory rate above 20/min, or PCO2 below 32 mmHg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than < 4,000/μl or less than 10% of bands.
  • Clinically suspected infection;

Exclusion Criteria:

  • were under 18 years of age;
  • were refused by the patients or his/her familiality;
  • were suffering from acquired immunodeficiency syndrome,virlhepatitis,autoimmune diseases and hematology;
  • use medicine which can affect immune system,such as Glucocorticoid and Immunosuppressant
  • died within 24h after being taken into the ICU, or refused to get involved in the study, or gave up treatment during the period of observation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01494389

China, Beijing
Chinese PLA General Hospital
Beijing, Beijing, China, 100853
Sponsors and Collaborators
Chinese PLA General Hospital
Study Director: Xie Li Xin, Doctor Department Of Respiratory Diseases, Chinese PLA General Hospital
  More Information

ClinicalTrials.gov Identifier: NCT01494389     History of Changes
Other Study ID Numbers: 20111013-008
First Submitted: December 16, 2011
First Posted: December 19, 2011
Last Update Posted: December 19, 2011
Last Verified: July 2011

Keywords provided by Chinese PLA General Hospital:
CD4+T lymphocyte subsets

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes